British Association of Dermatologists
Therapy & Guidelines sub-committee

Comments on the NICE Appraisal Consultation Document (ACD) for the Single Technology Appraisal (STA) on ustekinumab for treating active and progressive psoriatic arthritis

The Appraisal committee has asked for several points to be commented on:

1. Has all of the relevant evidence been taken into account?
   The two main phase III studies PSUMMIT I and PSUMMIT II have been included. An earlier Phase II study published in 2009 by Gottlieb et al. was not included.

2. Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?
   Yes, the interpretations are reasonable.

3. Are the provisional recommendations sound and a suitable basis for guidance to the NHS?
   Yes, we feel that in general the recommendations are sound and a suitable basis for the NHS, and highlight that further research is needed. There is a case, however, for giving approval for use in certain patients who are not suitable for TNF inhibitor therapy and who will be disadvantaged by the current recommendations.